In the world
Stago Group Companies
QualirisOur International External Quality Assessment (EQA) program for Hemostasis organized by a Proficiency Testing provider accredited to the ISO 17043 standard.
Stago webinarsStago provides you with the latest information regarding new tests, new markers or key assays for Thrombosis and Hemostasis. These educational sessions are provided by healthcare professionals and international key opinion leaders in the field.

Multiple Areas of Expertise Devoted Entirely to Haemostasis

The primary mission of the Research & Development (R&D) division of the Stago Group is to design products and solutions (automatic analysers, reagents, consumables, services, etc.) that meet the needs of biologists and clinicians, with the goal of improving treatment for clotting disorders and thrombosis. Working alongside the scientific community, R&D also focuses on identifying and studying new markers and methods for exploration in these areas.

The Desire and Means to Innovate

  • Since its creation, Stago has consistently developed its products and introduced the methods necessary for their control, development and industrial production.
  • Today, with more than 20% of its staff in Research & Development (R&D) and a level of investment higher than average for the In Vitro Diagnostic (IVD) sector, the Stago Group is determined to innovate in the field of haemostasis and thrombosis, with development teams in instrumentation and reagents, as well as prospective research teams and numerous scientific collaborations with university research teams.
  • The ability to develop complete systems (instruments + reagents + consumables + services) requires a variety of constantly changing skills, not just at the biological and clinical level, but also in chemistry, physics, mechanics, electronics, fluid science, optics, data processing, statistics and ergonomics, among other fields.
  • Finally, Stago must also remain abreast of the changes expected by customers throughout the life cycle of its products. Stago has consequently introduced a system of continuous improvement within its R&D division and in the Industrial & Supply Chain division, in which all of these areas of professional activity play a critical role.

An Outward Looking Policy …

  • The world of healthcare and medical technology has witnessed increasingly rapid change over the last 15 years, particularly in biology (genetics, new markers, automation, regulation, etc.). Levels of expertise and know-how have been rising constantly and must continually incorporate the latest advances in order to anticipate future developments. Monitoring of the technological, scientific and medical domains is thus essential to ensure in-house development and integration of these new skills.
  • For example, in our sector it is essential to adapt, transpose and develop concepts and technologies from other fields in order to endow our products with key functions and characteristics guaranteeing differentiation (quality, reliability, productivity, precision, ergonomics, etc.).
  • Similarly, the acquisition of companies such as Biocytex (1994) for cellular haemostasis and of Thrombinoscope and Synapse (2009) for thrombin generation provide ample evidence of Stago's continuing quest to expand its skills in the haemostasis field.

…in Synergy with the International Scientific Community

Since 1962, the Stago Group has concentrated its attention on biology, specialising in the "emerging" sector of haemostasis. Thanks to this clear focus, the group is now recognised worldwide by the scientific community in this field. Stago continues to maintain and develop strong links with the haemostasis community on a day-to-day basis by:

  • Ensuring optimal presence at scientific events.
  • Initiating and participating in studies with the foremost international university teams, thereby generating numerous scientific publications and communications.
  • Organising regular meetings with actors in the healthcare sphere in order to better understand the needs of biologists and provide them with continually improving levels of service to ensure better therapy for their patients.
  • Proposing subjects for collaboration concerning upstream research projects in order to discover and validate new areas and tools for investigation comprising a high degree of added medical value.

Top

Principal Production Centres in France

  • Instrumentation production: Gennevilliers
  • Plasma haemostasis: Franconville & Taverny (reagents)
  • Cellular haemostasis: Marseille (Biocytex)
  • Starting materials: La Ferté Saint Aubin (Agro-Bio) & Gennevilliers 

… as well as in Europe and the US

  • Thrombin generation: Maastricht - The Netherlands (Thrombinoscope, Synapse)
  • Plasma haemostasis Bray - Ireland (reagents& instruments), Lemgo -D (instruments) Clarkston-GA, USA (reagents)